Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

September 30, 2008

Study Completion Date

October 31, 2008

Conditions
Carcinoma, Renal Cell
Interventions
DRUG

Sorafenib

The initial dose of Sorafenib will be administered orally with a dose of 400 mg twice a day, daily. Intrapatient dose escalation will occur as defined in the protocol, providing no dose limiting toxicity (Grade 3 or 4) is observed.

Trial Locations (1)

77030

Methodist Hospital - Baylor College of Medicine, Houston

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

Bayer

INDUSTRY

collaborator

Amgen

INDUSTRY

lead

The Methodist Hospital Research Institute

OTHER

NCT00445042 - Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer | Biotech Hunter | Biotech Hunter